Mining Sequential Patterns of Diseases Contracted and Medications Prescribed before the Development of Stevens-Johnson Syndrome in Taiwan

Medication is designed to cure diseases, but serious risks can arise from severe adverse drug reactions (ADRs). ADRs can lead to emergency room visits and hospitalization, straining healthcare resources and, thus, they have strong implications for public health. Stevens–Johnson Syndrome (SJS) is one ADR and comprises the highest proportion of all drug relief cases in Taiwan. Pharmacovigilance involves the collection, detection, assessment, monitoring, and prevention of ADRs, including SJS. Most medical specialists are not fully aware of the risk of drug-induced SJS. Consequently, various drugs may be prescribed to susceptible patients for a great variety of diseases and, in turn, cause SJS. In this research, medical records of SJS patients were retrieved from the Taiwan National Health Insurance Research Database, and the Generalized Sequential Patterns (GSP) algorithm was used to find the sequential patterns of diseases before SJS onset. Then we mined the sequential patterns of medications prescribed in each disease pattern. Afterwards, we detected significant associations of each pattern of diseases and medications prescribed among age groups with statistical analysis. We found that, first, most patients developed SJS after being prescribed the causative medications fewer than four times. Second, Respiratory System Diseases (RSDs) appeared in disease sequential patterns of all lengths. Patterns involving RSDs were more frequent than others. Third, NSAIDs, H2-antagonists for peptic ulcer, penicillin antibiotics, theophylline bronchodilators, and cephalosporin antibiotics were the most frequent medications prescribed. Fourth, we found that patients in certain age groups had higher risks of developing SJS. This study aimed to mine the sequential patterns of diseases contracted and medications prescribed before patients developed SJS in Taiwan. This useful information can be provided to physicians so that they can stop the administration of suspected drugs to avoid evolution towards more severe cases.

[1]  A. Mawson,et al.  Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis (SJS/TEN): Could Retinoids Play a Causative Role? , 2015, Medical science monitor : international medical journal of experimental and clinical research.

[2]  Han-Cheng Wang,et al.  Developing a data mining approach to investigate association between physician prescription and patient outcome - A study on re-hospitalization in Stevens-Johnson Syndrome , 2013, Comput. Methods Programs Biomed..

[3]  Munir Pirmohamed,et al.  Fortnightly review: Adverse drug reactions , 1998 .

[4]  Ramakrishnan Srikant,et al.  Mining sequential patterns , 1995, Proceedings of the Eleventh International Conference on Data Engineering.

[5]  D. Pollock,et al.  National surveillance of emergency department visits for outpatient adverse drug events in children and adolescents. , 2008, The Journal of pediatrics.

[6]  Ramakrishnan Srikant,et al.  Mining Sequential Patterns: Generalizations and Performance Improvements , 1996, EDBT.

[7]  U. Raucci,et al.  Stevens-Johnson Syndrome Associated with Drugs and Vaccines in Children: A Case-Control Study , 2013, PloS one.

[8]  Y. Kinosada,et al.  Analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis using the Japanese Adverse Drug Event Report database , 2016, Journal of Pharmaceutical Health Care and Sciences.

[9]  R. Abe.  Toxic epidermal necrolysis and Stevens-Johnson syndrome: soluble Fas ligand involvement in the pathomechanisms of these diseases. , 2008, Journal of dermatological science.

[10]  D. Pollock,et al.  National surveillance of emergency department visits for outpatient adverse drug events. , 2006, JAMA.

[11]  R. Stern,et al.  Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. , 1996, The New England journal of medicine.

[12]  A. Stevens,et al.  A NEW ERUPTIVE FEVER ASSOCIATED WITH STOMATITIS AND OPHTHALMIA: REPORT OF TWO CASES IN CHILDREN , 1922 .

[13]  Yuan-Tsong Chen,et al.  A marker for Stevens–Johnson syndrome , 2004 .

[14]  M. Pirmohamed,et al.  ADVERSE DRUG REACTIONS , 1976, BMJ.

[15]  Benjamin Momo Kadia,et al.  Ivermectin induced Steven–Johnsons syndrome: case report , 2017, BMC Research Notes.

[16]  Wei Ding,et al.  Mining Adverse Drug Reactions from Electronic Health Records , 2013, 2013 IEEE 13th International Conference on Data Mining Workshops.

[17]  R. Stern,et al.  Using a claims database to investigate drug-induced Stevens-Johnson syndrome. , 1991, Statistics in medicine.

[18]  M. Mockenhaupt,et al.  Stevens‐Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN): Evaluation for drug risk based on sale numbers in defined daily doses (DDD). Example of the H2‐antagonists , 1995 .

[19]  J. Gõmez Orbaneja,et al.  [Toxic epidermal necrolysis]. , 1967, Revista clinica espanola.

[20]  A. Pariente,et al.  Data mining on electronic health record databases for signal detection in pharmacovigilance: which events to monitor? , 2009, Pharmacoepidemiology and drug safety.

[21]  Yuan-Tsong Chen,et al.  Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis , 2008, Nature Medicine.

[22]  Yong Hu,et al.  Data mining methodologies for pharmacovigilance , 2012, SKDD.

[23]  J. Roujeau,et al.  Toxic epidermal necrolysis and Stevens-Johnson syndrome: does early withdrawal of causative drugs decrease the risk of death? , 2000, Archives of dermatology.

[24]  Uzi Brook.  Stevens-Johnson syndrome and abnormal root development: a case report. , 1994, International journal of paediatric dentistry.

[25]  D. Madigan,et al.  The role of data mining in pharmacovigilance , 2005, Expert opinion on drug safety.

[26]  Y. Tay,et al.  Profile and pattern of Stevens-Johnson syndrome and toxic epidermal necrolysis in a general hospital in Singapore: treatment outcomes. , 2012, Acta dermato-venereologica.

[27]  H. Asada,et al.  Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens–Johnson syndrome and toxic epidermal necrolysis , 2015, The Journal of dermatology.

[28]  S. Jee,et al.  Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions , 2006, Pharmacogenetics and genomics.

[29]  T. Mersfelder,et al.  Severe adverse skin reactions to nonsteroidal antiinflammatory drugs: A review of the literature. , 2010, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[30]  M. Mockenhaupt,et al.  Stevens–Johnson Syndrome/Toxic Epidermal Necrolysis: Are Drug Dictionaries Correctly Informing Physicians Regarding the Risk? , 2013, Drug Safety.

[31]  C. Zachariae,et al.  [Stevens-Johnson syndrome and toxic epidermal necrolysis]. , 2013, Ugeskrift for laeger.

[32]  Antonio Gomariz,et al.  The SPMF Open-Source Data Mining Library Version 2 , 2016, ECML/PKDD.

[33]  F. Chang,et al.  Ranitidine‐related Stevens–Johnson syndrome in patients with severe liver diseases: A report of two cases , 2001, Journal of gastroenterology and hepatology.

[34]  L. French,et al.  Toxic epidermal necrolysis and Stevens-Johnson syndrome , 2010, Orphanet journal of rare diseases.

[35]  E. Sutedja,et al.  Stevens-Johnson syndrome and toxic epidermal necrolysis in Dr. Hasan Sadikin General Hospital Bandung, Indonesia from 2009-2013 , 2016, Asia Pacific allergy.

[36]  W. Sweileh,et al.  Bibliometric analysis of literature on toxic epidermal necrolysis and Stevens-Johnson syndrome: 1940 – 2015 , 2017, Orphanet Journal of Rare Diseases.

[37]  Nkanyezi N. Ferguson.  Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis , 2018 .

[38]  L. Naldi,et al.  Stevens-Johnson syndrome and toxic epidermal necrolysis: assessment of medication risks with emphasis on recently marketed drugs. The EuroSCAR-study. , 2008, The Journal of investigative dermatology.

[39]  F. Hsiao,et al.  Using Taiwan's National Health Insurance research database for pharmacoepidemiology research , 2020 .